StreetInsider.com News Articles

Form 20-F PolyPid Ltd. For: Dec 31

Wed, 25 Feb 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260225/26059569.html

Form 20-F PolyPid Ltd. For: Dec 31

Wed, 25 Feb 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260225/26059569.html

PolyPid Announces Participation in Upcoming Investor Conferences

Wed, 25 Feb 2026 08:35:00 -0500

PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026.

Citizens 2026 Life Sciences Conference

Date: March 10, 2026 at 1:40 pm ET
Location: Eden Roc Miami Beach, Miami Beach, FL
Format: Fireside chat
Webcast Signup: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/bygPbooQTs4VTXiUdoDYrb

Investors who wish to meet with PolyPid management should contact their Citizens representative to request

PolyPid Announces Participation in Upcoming Investor Conferences

Wed, 25 Feb 2026 08:35:00 -0500

PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026.

Citizens 2026 Life Sciences Conference

Date: March 10, 2026 at 1:40 pm ET
Location: Eden Roc Miami Beach, Miami Beach, FL
Format: Fireside chat
Webcast Signup: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/bygPbooQTs4VTXiUdoDYrb

Investors who wish to meet with PolyPid management should contact their Citizens representative to request

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 11 Feb 2026 12:10:00 -0500
si-local-file:///var/storage/secattach/20260211/25981833.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 11 Feb 2026 12:10:00 -0500
si-local-file:///var/storage/secattach/20260211/25981833.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 11 Feb 2026 12:10:00 -0500
si-local-file:///var/storage/secattach/20260211/25981834.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 11 Feb 2026 12:10:00 -0500
si-local-file:///var/storage/secattach/20260211/25981834.html

PolyPid Ltd. (PYPD) Misses Q4 EPS by 8c

Wed, 11 Feb 2026 07:41:42 -0500

PolyPid Ltd. (NASDAQ: PYPD) reported Q4 EPS of ($0.41), $0.08 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on PolyPid Ltd. (PYPD) click here.

Form 6-K PolyPid Ltd. For: Feb 11

Wed, 11 Feb 2026 07:36:00 -0500
si-local-file:///var/storage/secattach/20260211/25979479.html

Form 6-K PolyPid Ltd. For: Feb 11

Wed, 11 Feb 2026 07:36:00 -0500
si-local-file:///var/storage/secattach/20260211/25979479.html

PolyPid advances D-PLEX100 partnership talks, plans NDA filing

Wed, 11 Feb 2026 07:31:32 -0500

PolyPid Ltd. (NASDAQ: PYPD) reported fourth quarter and full-year 2025 financial results while announcing progress in commercial partnership discussions for its D-PLEX100 drug and regulatory preparations for a New Drug Application submission.
The Israeli biopharmaceutical company stated it has entered advanced stages of discussions for a potential commercial partnership in the United States for D-PLEX100, which targets prevention of abdominal colorectal surgical site infections. The company received positive feedback from the FDA following a pre-NDA meeting and plans to begin rolling NDA submission by the end of the first quarter of 2026.
PolyPid appointed Brooke Story as Chairman of the Board of

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Wed, 11 Feb 2026 07:30:00 -0500

The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀

Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026

Conference Call Scheduled for Today at 8:30 AM ET

PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months and full

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Wed, 11 Feb 2026 07:30:00 -0500

The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀

Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026

Conference Call Scheduled for Today at 8:30 AM ET

PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months and full

Form 6-K PolyPid Ltd. For: Feb 04

Wed, 04 Feb 2026 16:05:00 -0500
si-local-file:///var/storage/secattach/20260204/25946829.html

Form 6-K PolyPid Ltd. For: Feb 04

Wed, 04 Feb 2026 16:05:00 -0500
si-local-file:///var/storage/secattach/20260204/25946829.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: HIRSCHMAN ORIN

Fri, 30 Jan 2026 13:03:00 -0500
si-local-file:///var/storage/secattach/20260130/25921926.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: HIRSCHMAN ORIN

Fri, 30 Jan 2026 13:03:00 -0500
si-local-file:///var/storage/secattach/20260130/25921926.html

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Wed, 28 Jan 2026 08:00:00 -0500

PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Wed, 28 Jan 2026 08:00:00 -0500

PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum

Form 6-K PolyPid Ltd. For: Dec 31

Wed, 31 Dec 2025 16:01:00 -0500
si-local-file:///var/storage/secattach/20251231/25794400.html

Form 6-K PolyPid Ltd. For: Dec 31

Wed, 31 Dec 2025 16:01:00 -0500
si-local-file:///var/storage/secattach/20251231/25794400.html

Form 6-K PolyPid Ltd. For: Dec 16

Tue, 16 Dec 2025 08:35:00 -0500
si-local-file:///var/storage/secattach/20251216/25744247.html

Form 6-K PolyPid Ltd. For: Dec 16

Tue, 16 Dec 2025 08:35:00 -0500
si-local-file:///var/storage/secattach/20251216/25744247.html

PolyPid names Brooke Story as board chairman

Tue, 16 Dec 2025 08:30:13 -0500

PolyPid Ltd. (NASDAQ: PYPD) appointed Brooke Story as chairman of the board of directors, effective December 11, 2025, according to a press release statement.

Story brings over 25 years of experience in the medical technology industry, having held senior roles at BD (Becton, Dickinson and Company) and Medtronic PLC. She previously served as worldwide president of BD's surgery business, overseeing global strategy and profit-and-loss responsibility for portfolios in hernia repair, tissue repair and infection prevention.

Story currently serves as BD's separation and integration lead, managing the life sciences divestiture and ongoing global integrations. She also serves as a non-executive director on the